No Cover Image

Journal article 1135 views 1319 downloads

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean-Jacques Grob, C. Lance Cowey, Christopher D. Lao, John Wagstaff, Dirk Schadendorf, Pier F. Ferrucci, Michael Smylie, Reinhard Dummer, Andrew Hill, David Hogg, John Haanen, Matteo S. Carlino, Oliver Bechter, Michele Maio, Ivan Marquez-Rodas, Massimo Guidoboni, Grant McArthur, Celeste Lebbé, Paolo A. Ascierto, Georgina V. Long, Jonathan Cebon, Jeffrey Sosman, Michael A. Postow, Margaret K. Callahan, Dana Walker, Linda Rollin, Rafia Bhore, F. Stephen Hodi, James Larkin

New England Journal of Medicine, Volume: 377, Issue: 14, Pages: 1345 - 1356

Swansea University Author: John Wagstaff

Check full text

DOI (Published version): 10.1056/nejmoa1709684

Abstract

This is the three year update of a randomised phase III trial in patients with locally advanced inoperable stage III or stage IV melanoma. 1296 patients were radomised to receive either ipilimumab (Ipi), nivolumab (Nivo) or both antibodies (Ipi+Nivo). Complete responses were seen in 5, 16 & 19%...

Full description

Published in: New England Journal of Medicine
ISSN: 0028-4793 1533-4406
Published: Massachusetts Medical Society 2017
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa37736
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2017-12-26T20:21:33Z
last_indexed 2020-08-07T03:01:32Z
id cronfa37736
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2020-08-06T12:31:03.5021248</datestamp><bib-version>v2</bib-version><id>37736</id><entry>2017-12-26</entry><title>Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma</title><swanseaauthors><author><sid>fdab5e9e2fe06c93d3ffa19c816bdcf6</sid><firstname>John</firstname><surname>Wagstaff</surname><name>John Wagstaff</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2017-12-26</date><deptcode>SGMED</deptcode><abstract>This is the three year update of a randomised phase III trial in patients with locally advanced inoperable stage III or stage IV melanoma. 1296 patients were radomised to receive either ipilimumab (Ipi), nivolumab (Nivo) or both antibodies (Ipi+Nivo). Complete responses were seen in 5, 16 &amp; 19% of patients in the Ipi, Nivo and Ipi+Nivo groups respectively. Partial responses were seen in 14, 28 &amp; 29% of patients respectively. With a minimum follow up of 28 months 3 year overall survivals were 32, 52 &amp; 58% in the Ipi, Nivo &amp; Ipi+Nivo respectively. In patients with braf mutations the three year survivals were 37, 56 &amp; 68% in the three groups. This compares with a three year survival of 44% in the dabrafenib plus trametinib arm of the COMBI-D trial (J. Clin. Oncol. 2017 Dob: 10.1200/JCO.2017.74.1025). These data represent practice changing data for oncologist who treat melanoma and life changing treatment for patients with metastatic melanoma.</abstract><type>Journal Article</type><journal>New England Journal of Medicine</journal><volume>377</volume><journalNumber>14</journalNumber><paginationStart>1345</paginationStart><paginationEnd>1356</paginationEnd><publisher>Massachusetts Medical Society</publisher><issnPrint>0028-4793</issnPrint><issnElectronic>1533-4406</issnElectronic><keywords>Melanoma, Ipilimumab, Nivolumab, Survival</keywords><publishedDay>5</publishedDay><publishedMonth>10</publishedMonth><publishedYear>2017</publishedYear><publishedDate>2017-10-05</publishedDate><doi>10.1056/nejmoa1709684</doi><url>http://dx.doi.org/10.1056/nejmoa1709684</url><notes/><college>COLLEGE NANME</college><department>Medical School - School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>SGMED</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2020-08-06T12:31:03.5021248</lastEdited><Created>2017-12-26T13:24:28.7708033</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Jedd D.</firstname><surname>Wolchok</surname><order>1</order></author><author><firstname>Vanna</firstname><surname>Chiarion-Sileni</surname><order>2</order></author><author><firstname>Rene</firstname><surname>Gonzalez</surname><order>3</order></author><author><firstname>Piotr</firstname><surname>Rutkowski</surname><order>4</order></author><author><firstname>Jean-Jacques</firstname><surname>Grob</surname><order>5</order></author><author><firstname>C. Lance</firstname><surname>Cowey</surname><order>6</order></author><author><firstname>Christopher D.</firstname><surname>Lao</surname><order>7</order></author><author><firstname>John</firstname><surname>Wagstaff</surname><order>8</order></author><author><firstname>Dirk</firstname><surname>Schadendorf</surname><order>9</order></author><author><firstname>Pier F.</firstname><surname>Ferrucci</surname><order>10</order></author><author><firstname>Michael</firstname><surname>Smylie</surname><order>11</order></author><author><firstname>Reinhard</firstname><surname>Dummer</surname><order>12</order></author><author><firstname>Andrew</firstname><surname>Hill</surname><order>13</order></author><author><firstname>David</firstname><surname>Hogg</surname><order>14</order></author><author><firstname>John</firstname><surname>Haanen</surname><order>15</order></author><author><firstname>Matteo S.</firstname><surname>Carlino</surname><order>16</order></author><author><firstname>Oliver</firstname><surname>Bechter</surname><order>17</order></author><author><firstname>Michele</firstname><surname>Maio</surname><order>18</order></author><author><firstname>Ivan</firstname><surname>Marquez-Rodas</surname><order>19</order></author><author><firstname>Massimo</firstname><surname>Guidoboni</surname><order>20</order></author><author><firstname>Grant</firstname><surname>McArthur</surname><order>21</order></author><author><firstname>Celeste</firstname><surname>Lebb&#xE9;</surname><order>22</order></author><author><firstname>Paolo A.</firstname><surname>Ascierto</surname><order>23</order></author><author><firstname>Georgina V.</firstname><surname>Long</surname><order>24</order></author><author><firstname>Jonathan</firstname><surname>Cebon</surname><order>25</order></author><author><firstname>Jeffrey</firstname><surname>Sosman</surname><order>26</order></author><author><firstname>Michael A.</firstname><surname>Postow</surname><order>27</order></author><author><firstname>Margaret K.</firstname><surname>Callahan</surname><order>28</order></author><author><firstname>Dana</firstname><surname>Walker</surname><order>29</order></author><author><firstname>Linda</firstname><surname>Rollin</surname><order>30</order></author><author><firstname>Rafia</firstname><surname>Bhore</surname><order>31</order></author><author><firstname>F. Stephen</firstname><surname>Hodi</surname><order>32</order></author><author><firstname>James</firstname><surname>Larkin</surname><order>33</order></author></authors><documents><document><filename>0037736-09022018100623.pdf</filename><originalFilename>37736.pdf</originalFilename><uploaded>2018-02-09T10:06:23.4230000</uploaded><type>Output</type><contentLength>298810</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><embargoDate>2018-04-05T00:00:00.0000000</embargoDate><copyrightCorrect>true</copyrightCorrect><language>eng</language></document></documents><OutputDurs/></rfc1807>
spelling 2020-08-06T12:31:03.5021248 v2 37736 2017-12-26 Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma fdab5e9e2fe06c93d3ffa19c816bdcf6 John Wagstaff John Wagstaff true false 2017-12-26 SGMED This is the three year update of a randomised phase III trial in patients with locally advanced inoperable stage III or stage IV melanoma. 1296 patients were radomised to receive either ipilimumab (Ipi), nivolumab (Nivo) or both antibodies (Ipi+Nivo). Complete responses were seen in 5, 16 & 19% of patients in the Ipi, Nivo and Ipi+Nivo groups respectively. Partial responses were seen in 14, 28 & 29% of patients respectively. With a minimum follow up of 28 months 3 year overall survivals were 32, 52 & 58% in the Ipi, Nivo & Ipi+Nivo respectively. In patients with braf mutations the three year survivals were 37, 56 & 68% in the three groups. This compares with a three year survival of 44% in the dabrafenib plus trametinib arm of the COMBI-D trial (J. Clin. Oncol. 2017 Dob: 10.1200/JCO.2017.74.1025). These data represent practice changing data for oncologist who treat melanoma and life changing treatment for patients with metastatic melanoma. Journal Article New England Journal of Medicine 377 14 1345 1356 Massachusetts Medical Society 0028-4793 1533-4406 Melanoma, Ipilimumab, Nivolumab, Survival 5 10 2017 2017-10-05 10.1056/nejmoa1709684 http://dx.doi.org/10.1056/nejmoa1709684 COLLEGE NANME Medical School - School COLLEGE CODE SGMED Swansea University 2020-08-06T12:31:03.5021248 2017-12-26T13:24:28.7708033 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Jedd D. Wolchok 1 Vanna Chiarion-Sileni 2 Rene Gonzalez 3 Piotr Rutkowski 4 Jean-Jacques Grob 5 C. Lance Cowey 6 Christopher D. Lao 7 John Wagstaff 8 Dirk Schadendorf 9 Pier F. Ferrucci 10 Michael Smylie 11 Reinhard Dummer 12 Andrew Hill 13 David Hogg 14 John Haanen 15 Matteo S. Carlino 16 Oliver Bechter 17 Michele Maio 18 Ivan Marquez-Rodas 19 Massimo Guidoboni 20 Grant McArthur 21 Celeste Lebbé 22 Paolo A. Ascierto 23 Georgina V. Long 24 Jonathan Cebon 25 Jeffrey Sosman 26 Michael A. Postow 27 Margaret K. Callahan 28 Dana Walker 29 Linda Rollin 30 Rafia Bhore 31 F. Stephen Hodi 32 James Larkin 33 0037736-09022018100623.pdf 37736.pdf 2018-02-09T10:06:23.4230000 Output 298810 application/pdf Version of Record true 2018-04-05T00:00:00.0000000 true eng
title Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
spellingShingle Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
John Wagstaff
title_short Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
title_full Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
title_fullStr Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
title_full_unstemmed Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
title_sort Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
author_id_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6
author_id_fullname_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6_***_John Wagstaff
author John Wagstaff
author2 Jedd D. Wolchok
Vanna Chiarion-Sileni
Rene Gonzalez
Piotr Rutkowski
Jean-Jacques Grob
C. Lance Cowey
Christopher D. Lao
John Wagstaff
Dirk Schadendorf
Pier F. Ferrucci
Michael Smylie
Reinhard Dummer
Andrew Hill
David Hogg
John Haanen
Matteo S. Carlino
Oliver Bechter
Michele Maio
Ivan Marquez-Rodas
Massimo Guidoboni
Grant McArthur
Celeste Lebbé
Paolo A. Ascierto
Georgina V. Long
Jonathan Cebon
Jeffrey Sosman
Michael A. Postow
Margaret K. Callahan
Dana Walker
Linda Rollin
Rafia Bhore
F. Stephen Hodi
James Larkin
format Journal article
container_title New England Journal of Medicine
container_volume 377
container_issue 14
container_start_page 1345
publishDate 2017
institution Swansea University
issn 0028-4793
1533-4406
doi_str_mv 10.1056/nejmoa1709684
publisher Massachusetts Medical Society
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
url http://dx.doi.org/10.1056/nejmoa1709684
document_store_str 1
active_str 0
description This is the three year update of a randomised phase III trial in patients with locally advanced inoperable stage III or stage IV melanoma. 1296 patients were radomised to receive either ipilimumab (Ipi), nivolumab (Nivo) or both antibodies (Ipi+Nivo). Complete responses were seen in 5, 16 & 19% of patients in the Ipi, Nivo and Ipi+Nivo groups respectively. Partial responses were seen in 14, 28 & 29% of patients respectively. With a minimum follow up of 28 months 3 year overall survivals were 32, 52 & 58% in the Ipi, Nivo & Ipi+Nivo respectively. In patients with braf mutations the three year survivals were 37, 56 & 68% in the three groups. This compares with a three year survival of 44% in the dabrafenib plus trametinib arm of the COMBI-D trial (J. Clin. Oncol. 2017 Dob: 10.1200/JCO.2017.74.1025). These data represent practice changing data for oncologist who treat melanoma and life changing treatment for patients with metastatic melanoma.
published_date 2017-10-05T03:47:33Z
_version_ 1763752283961556992
score 11.035874

Similar Items